These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21031547)

  • 1. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
    Cheung CK; Lo CM; Man K; Lau GK
    Liver Transpl; 2010 Nov; 16(11):1314-23. PubMed ID: 21031547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome.
    Rokuhara A; Tanaka E; Yagi S; Mizokami M; Hashikura Y; Kawasaki S; Kiyosawa K
    J Med Virol; 2000 Dec; 62(4):471-8. PubMed ID: 11074476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.
    Wong DK; Yuen MF; Yuan H; Sum SS; Hui CK; Hall J; Lai CL
    Hepatology; 2004 Sep; 40(3):727-37. PubMed ID: 15349913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
    Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection.
    Caviglia GP; Abate ML; Tandoi F; Ciancio A; Amoroso A; Salizzoni M; Saracco GM; Rizzetto M; Romagnoli R; Smedile A
    J Hepatol; 2018 Aug; 69(2):301-307. PubMed ID: 29621551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis.
    Lenci I; Marcuccilli F; Tisone G; Di Paolo D; Tariciotti L; Ciotti M; Guenci T; Perno CF; Angelico M
    Dig Liver Dis; 2010 Aug; 42(8):578-84. PubMed ID: 20097143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
    Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
    J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change of hepatitis B virus DNA status in anti-HBc positive liver graft.
    Kwon CH; Suh KS; Cho JY; Yi NJ; Jang JJ; Lee KU
    Korean J Hepatol; 2006 Jun; 12(2):191-200. PubMed ID: 16804344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts.
    Niu Y; Chen X; Feng L; You H; Ren X; Liu H; Zheng J; Shen Z; Jia J
    Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):475-80. PubMed ID: 24835492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
    Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
    J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.